{"id":15102,"date":"2023-08-16T23:43:00","date_gmt":"2023-08-16T15:43:00","guid":{"rendered":"https:\/\/flcube.com\/?p=15102"},"modified":"2024-11-26T23:47:20","modified_gmt":"2024-11-26T15:47:20","slug":"yingli-pharmas-linperlislib-receives-priority-review-status-for-lymphoma-treatments","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=15102","title":{"rendered":"Yingli Pharma&#8217;s Linperlislib Receives Priority Review Status for Lymphoma Treatments"},"content":{"rendered":"\n<p>US-based Yingli Pharma, a company dedicated to developing drugs for both the Chinese and US markets, has announced that its drug linperlislib has been granted priority review status by the US Food and Drug Administration (FDA) for the treatment of adult patients with recurrent or refractory follicular lymphoma (FL) who have received at least two systemic treatments in the past, and adult patients with recurrent and\/or refractory peripheral T\/NK cell lymphoma who have received first-line sufficient treatment in the past. The priority review status is attributed to the drug being &#8220;eligible for conditional approval&#8221;.<\/p>\n\n\n\n<p><strong>Linperlislib: A Potent PI3K\u03b4 Inhibitor<\/strong><br>Linperlislib is a highly selective and potent PI3K\u03b4 inhibitor that was conditionally approved to treat recurrent\/refractory (R\/R) follicular lymphoma (FL) in November last year. The drug is set to be co-promoted by Hengrui Medicine in China, expanding its reach and impact in the market.<\/p>\n\n\n\n<p><strong>Recognition and Support for Linperlislib<\/strong><br>The drug has been recognized and included in the 2022 Shanghai Biomedical &#8220;New Excellent Drugs and Devices&#8221; List and the Shanghai First Recommended Batch Products List in 2023. These inclusions indicate municipal support for linperlislib, highlighting its potential as a valuable treatment option moving forward.<a href=\"https:\/\/flcube.com\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>US-based Yingli Pharma, a company dedicated to developing drugs for both the Chinese and US&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[16,80,1870],"class_list":["post-15102","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-cancer","tag-priority-reviews","tag-yingli-pharma"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Yingli Pharma&#039;s Linperlislib Receives Priority Review Status for Lymphoma Treatments - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"US-based Yingli Pharma, a company dedicated to developing drugs for both the Chinese and US markets, has announced that its drug linperlislib has been granted priority review status by the US Food and Drug Administration (FDA) for the treatment of adult patients with recurrent or refractory follicular lymphoma (FL) who have received at least two systemic treatments in the past, and adult patients with recurrent and\/or refractory peripheral T\/NK cell lymphoma who have received first-line sufficient treatment in the past. The priority review status is attributed to the drug being &quot;eligible for conditional approval&quot;.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=15102\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Yingli Pharma&#039;s Linperlislib Receives Priority Review Status for Lymphoma Treatments\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=15102\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2023-08-16T15:43:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-11-26T15:47:20+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=15102#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=15102\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Yingli Pharma&#8217;s Linperlislib Receives Priority Review Status for Lymphoma Treatments\",\"datePublished\":\"2023-08-16T15:43:00+00:00\",\"dateModified\":\"2024-11-26T15:47:20+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=15102\"},\"wordCount\":212,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Cancer\",\"Priority reviews\",\"Yingli Pharma\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=15102#respond\"]}],\"copyrightYear\":\"2023\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=15102\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=15102\",\"name\":\"Yingli Pharma's Linperlislib Receives Priority Review Status for Lymphoma Treatments - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2023-08-16T15:43:00+00:00\",\"dateModified\":\"2024-11-26T15:47:20+00:00\",\"description\":\"US-based Yingli Pharma, a company dedicated to developing drugs for both the Chinese and US markets, has announced that its drug linperlislib has been granted priority review status by the US Food and Drug Administration (FDA) for the treatment of adult patients with recurrent or refractory follicular lymphoma (FL) who have received at least two systemic treatments in the past, and adult patients with recurrent and\\\/or refractory peripheral T\\\/NK cell lymphoma who have received first-line sufficient treatment in the past. The priority review status is attributed to the drug being \\\"eligible for conditional approval\\\".\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=15102#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=15102\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=15102#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Yingli Pharma&#8217;s Linperlislib Receives Priority Review Status for Lymphoma Treatments\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Yingli Pharma's Linperlislib Receives Priority Review Status for Lymphoma Treatments - Insight, China&#039;s Pharmaceutical Industry","description":"US-based Yingli Pharma, a company dedicated to developing drugs for both the Chinese and US markets, has announced that its drug linperlislib has been granted priority review status by the US Food and Drug Administration (FDA) for the treatment of adult patients with recurrent or refractory follicular lymphoma (FL) who have received at least two systemic treatments in the past, and adult patients with recurrent and\/or refractory peripheral T\/NK cell lymphoma who have received first-line sufficient treatment in the past. The priority review status is attributed to the drug being \"eligible for conditional approval\".","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=15102","og_locale":"en_US","og_type":"article","og_title":"Yingli Pharma's Linperlislib Receives Priority Review Status for Lymphoma Treatments","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=15102","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2023-08-16T15:43:00+00:00","article_modified_time":"2024-11-26T15:47:20+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=15102#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=15102"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Yingli Pharma&#8217;s Linperlislib Receives Priority Review Status for Lymphoma Treatments","datePublished":"2023-08-16T15:43:00+00:00","dateModified":"2024-11-26T15:47:20+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=15102"},"wordCount":212,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Cancer","Priority reviews","Yingli Pharma"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=15102#respond"]}],"copyrightYear":"2023","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=15102","url":"https:\/\/flcube.com\/?p=15102","name":"Yingli Pharma's Linperlislib Receives Priority Review Status for Lymphoma Treatments - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2023-08-16T15:43:00+00:00","dateModified":"2024-11-26T15:47:20+00:00","description":"US-based Yingli Pharma, a company dedicated to developing drugs for both the Chinese and US markets, has announced that its drug linperlislib has been granted priority review status by the US Food and Drug Administration (FDA) for the treatment of adult patients with recurrent or refractory follicular lymphoma (FL) who have received at least two systemic treatments in the past, and adult patients with recurrent and\/or refractory peripheral T\/NK cell lymphoma who have received first-line sufficient treatment in the past. The priority review status is attributed to the drug being \"eligible for conditional approval\".","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=15102#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=15102"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=15102#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Yingli Pharma&#8217;s Linperlislib Receives Priority Review Status for Lymphoma Treatments"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/15102","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=15102"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/15102\/revisions"}],"predecessor-version":[{"id":15104,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/15102\/revisions\/15104"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=15102"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=15102"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=15102"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}